Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in Refractory Guttate Psoriasis
NCT06374979Phase 3Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of ixekizumab in guttate psoriasis, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Planned start May 2025; status: not yet recruiting.
02
Drugs
ixekizumab
03
Conditions
guttate psoriasis
Beyond the preview
Go deeper on NCT06374979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06374979.